BTG, Protherics deal

BTG will acquire Protherics in a stock deal that values Protherics at £218.1 million ($393.3 million) or 60p per share. BTG said the deal price is a 46% premium to

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE